Evidence has shown that a reduction in the ADRB1/ADRB2 ratio has been observed in heart failure, and the use of adrenoceptor beta blockers is a cornerstone of current heart failure therapy (Baker, 2014; Woo et al., 2015). The gene discussed is ADRB1; the disease is heart failure.